Q3 2022 EPS Estimates for TRxADE HEALTH, Inc. (NASDAQ:MEDS) Reduced by Taglich Brothers

TRxADE HEALTH, Inc. (NASDAQ:MEDSGet Rating) – Stock analysts at Taglich Brothers decreased their Q3 2022 earnings estimates for shares of TRxADE HEALTH in a research report issued to clients and investors on Tuesday, August 2nd. Taglich Brothers analyst H. Halpern now expects that the company will post earnings per share of ($0.12) for the quarter, down from their prior estimate of ($0.09). The consensus estimate for TRxADE HEALTH’s current full-year earnings is ($0.40) per share. Taglich Brothers also issued estimates for TRxADE HEALTH’s Q4 2022 earnings at ($0.09) EPS, FY2022 earnings at ($0.45) EPS, Q1 2023 earnings at ($0.04) EPS, Q2 2023 earnings at ($0.02) EPS, Q3 2023 earnings at ($0.03) EPS and Q4 2023 earnings at ($0.05) EPS.

TRxADE HEALTH Price Performance

Shares of MEDS stock opened at $1.57 on Friday. The firm has a market cap of $12.84 million, a P/E ratio of -3.14 and a beta of 1.20. The company has a debt-to-equity ratio of 0.18, a current ratio of 1.31 and a quick ratio of 1.26. TRxADE HEALTH has a 1-year low of $1.16 and a 1-year high of $5.48. The firm has a fifty day moving average of $1.60 and a two-hundred day moving average of $1.80.

TRxADE HEALTH (NASDAQ:MEDSGet Rating) last announced its quarterly earnings data on Monday, July 25th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.05). TRxADE HEALTH had a negative return on equity of 86.76% and a negative net margin of 35.98%. During the same quarter last year, the business earned ($0.17) EPS.

Institutional Inflows and Outflows

An institutional investor recently raised its position in TRxADE HEALTH stock. Ridgewood Investments LLC grew its stake in shares of TRxADE HEALTH, Inc. (NASDAQ:MEDSGet Rating) by 42.7% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 200,600 shares of the company’s stock after buying an additional 60,000 shares during the quarter. Ridgewood Investments LLC owned about 2.45% of TRxADE HEALTH worth $325,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 8.43% of the company’s stock.

Insiders Place Their Bets

In other TRxADE HEALTH news, CEO Surendra K. Ajjarapu purchased 10,000 shares of the firm’s stock in a transaction dated Friday, May 20th. The stock was acquired at an average cost of $13,000.00 per share, with a total value of $130,000,000.00. Following the acquisition, the chief executive officer now owns 222,500 shares of the company’s stock, valued at approximately $2,892,500,000. The purchase was disclosed in a filing with the SEC, which is accessible through this link. 53.83% of the stock is owned by company insiders.

TRxADE HEALTH Company Profile

(Get Rating)

TRxADE HEALTH, Inc operates as a health services IT company in the United States. The company focuses on digitalizing the retail pharmacy experience by optimizing drug procurement, prescription journey, and patient engagement. It operates the TRxADE drug procurement marketplace, which fosters price transparency and serves approximately 11,800 members; and offers patient centric telehealth services under the Bonum Health brand name.

Further Reading

Receive News & Ratings for TRxADE HEALTH Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TRxADE HEALTH and related companies with MarketBeat.com's FREE daily email newsletter.